SAN Share Price

Open 82.10 Change Price %
High 83.75 1 Day 0.76 0.93
Low 82.10 1 Week 0.08 0.10
Close 82.67 1 Month -5.20 -5.92
Volume 2398290 1 Year 6.16 8.05
52 Week High 92.97
52 Week Low 66.72
SAN Important Levels
Resistance 2 84.20
Resistance 1 83.57
Pivot 82.84
Support 1 81.77
Support 2 81.14
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
ACA 14.85 2.34%
ACA 14.85 2.34%
More..
EPA France Top Gainers Stocks
MLLEM 0.55 41.03%
OXI 0.05 25.00%
OXI 0.05 25.00%
MLSAT 5.43 23.41%
ALSAS 12.00 16.50%
APAM 33.78 15.72%
APAM 33.78 15.72%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
MLKRI 3.17 -30.02%
VRNL 0.65 -27.78%
ALALO 0.07 -12.50%
HDP 1.81 -9.50%
ORAP 11.53 -7.69%
JXR 0.77 -7.23%
CIB 0.13 -7.14%
CIB 0.13 -7.14%
CIB 0.13 -7.14%
CIB 0.13 -7.14%
More..

Sanofi (EPA: SAN)

SAN Technical Analysis 2
As on 25th Jul 2017 SAN Share Price closed @ 82.67 and we RECOMMEND Buy for LONG-TERM with Stoploss of 78.92 & Strong Sell for SHORT-TERM with Stoploss of 86.38 we also expect STOCK to react on Following IMPORTANT LEVELS.
SAN Target for July
1st Target up-side 86.72
2nd Target up-side 88.8
3rd Target up-side 90.88
1st Target down-side 80.8
2nd Target down-side 78.72
3rd Target down-side 76.64
SAN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.sanofi-aventis.com
SAN Address
SAN
54, Rue La Bo
Paris, 75008
France
Phone: 33 1 53 77 40 00
Interactive Technical Analysis Chart Sanofi ( SAN EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Sanofi
SAN Business Profile
Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances with Bristol-Myers Squibb, Regeneron, Warner Chilcott, and Regulus Therapeutics Inc., as well as a strategic collaboration with UCB S.A. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.